110
Harvest One Cannabis Corp.(TSX-V:HVST)
Based on Cham, Switzerland, Harvest One’s medical and health brand, Satipharm, is specialized in the development and manufacturing of cannabis-health products. In 2017, Satipharm’s marketing campaign is focused on near-term growth and driving sales first in Germany and Poland with entry into additional European Union countries to follow. The company is concurrently preparing to import its products into Canada and on May 9th announced that it has shipped its first product order in Australia and is ready for distribution.
Satipharm is specialized in the development and production of dietary supplements with a focus on the legally accessible cannabidiol (CBD). From this development originated the CBD Gelpell Microgel Capsules, a CBD product with a unique, controlled delivery system with enhanced oral bioavailability.
The company’s March 13, 2017 press release states that,
“Satipharm has secured Pharmaceutical Central Numbers (PZN codes) for its 10mg and 50mg Gelpell-CBD Microgel Capsules, enabling both products to be sold in all pharmacies throughout Germany. The Company’s online distribution partner, German Bodfeld Pharmacy, has commenced the shipping of Satipharm’s cannabidiol (“CBD”) extract products to regulated markets globally, further enhancing the Company’s capacity to rapidly scale up product sales. Importantly, German Bodfeld Pharmacy accepts all major payment methods, which solves a key payment gateway issue imposed on CBD producers globally due to the federal U.S. ban of cannabinoids.”
CEO Andreas Gedeon reiterated Harvest One’s position of bringing Satipharm’s products “to international medical cannabis markets as legislation opens up is an integral part of the company’s aggressive growth strategy” and their recent shipment to Australia reinforces the importance of being a first mover in these new emerging markets and to becoming global players in the industry.